Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Advanced Solid Tumor × Gemcitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 141 Carcinoma, Non-Small-Cell Lung 77 Neoplasms 47 Breast Neoplasms 45 Urinary Bladder Neoplasms 42 Neoplasm Metastasis 36 Lung Neoplasms 34 Ovarian Neoplasms 29 Cholangiocarcinoma 25 Lymphoma 17 Gallbladder Neoplasms 16 Fallopian Tube Neoplasms 16 Sarcoma 15 Lymphoma, Large B-Cell, Diffuse 15 Biliary Tract Neoplasms 14 Lymphoma, Non-Hodgkin 12 Carcinoma, Transitional Cell 12 Carcinoma 12 Recurrence 11 Hodgkin Disease 11 Bile Duct Neoplasms 11 Adenocarcinoma 11 Head and Neck Neoplasms 8 Colorectal Neoplasms 8 Carcinoma, Renal Cell 8 Urethral Neoplasms 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Triple Negative Breast Neoplasms 6 Uterine Cervical Neoplasms 5 Ureteral Neoplasms 5

Interventions

ulixertinib 1 tislelizumab 1 talazoparib 1 olaparib 1 lenvatinib 1 erdafitinib 1 atezolizumab 1 Ramucirumab 1 PM 01183 1 Injections 1 IFL protocol 1 Gemcitabine 1 Bosentan 1 BID protein, human 1 Appointments and Schedules 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04497116 2025-10-21

TRESR

Repare Therapeutics

Phase 1/2 Completed

276 enrolled 33 charts

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡